Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study. Zhou L, Wu X, Chi Z, Si L, et al. BMC Cancer 2022;22:565.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhou L, Wu X, Chi Z, Si L, et al. Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study. BMC Cancer 2022;22:565.
PMID: 35596181